Preoperative Immune Checkpoint Inhibitor Therapy and Perioperative Cardiovascular Complications after Noncardiac Cancer Surgery: The REMIOS-ICI Study

Read full text Summarise with VIRAT
Authors: Shaoyong Wu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This observational cohort study uses retrospective data from the REMIOS project (2013–2022) to evaluate the association between preoperative immune checkpoint inhibitor (ICI) exposure within six months and perioperative cardiovascular complications. Adult patients undergoing intermediate- to high-risk noncardiac cancer surgery are categorized into ICI-exposed and unexposed groups. Primary outcomes are 30-day myocardial injury (MINS) and major adverse cardiovascular events (MACE), with secondary outcomes of 30-day mortality and 7-day acute kidney injury. Confounding is controlled via doubly robust estimation. The study aims to clarify whether recent ICI therapy increases perioperative cardiovascular risk, informing perioperative management in this growing patient population.

Fields of Study & Subjects

Cardiac Anesthesia and Surgical Outcomes Cancer Immunotherapy and Biomarkers Chemotherapy-induced cardiotoxicity and mitigation

Publication details

Journal / source
Open Science Framework
Publication date
1 January 2026
Language
EN